Christopher Liu
Stock Analyst at Leerink Partners
(3.00)
# 1,127
Out of 4,829 analysts
5
Total ratings
100%
Success rate
65.25%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Christopher Liu
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| RLAY Relay Therapeutics | Maintains: Outperform | $19 → $18 | $3.11 | +478.78% | 1 | Dec 4, 2024 | |
| IDYA IDEAYA Biosciences | Downgrades: Market Perform | $41 → $27 | $18.37 | +46.98% | 2 | Nov 5, 2024 | |
| NUVL Nuvalent | Initiates: Market Perform | $42 | $73.63 | -42.96% | 1 | Aug 8, 2023 | |
| EXEL Exelixis | Initiates: Market Perform | $18 | $36.98 | -51.33% | 1 | Aug 8, 2023 |
Relay Therapeutics
Dec 4, 2024
Maintains: Outperform
Price Target: $19 → $18
Current: $3.11
Upside: +478.78%
IDEAYA Biosciences
Nov 5, 2024
Downgrades: Market Perform
Price Target: $41 → $27
Current: $18.37
Upside: +46.98%
Nuvalent
Aug 8, 2023
Initiates: Market Perform
Price Target: $42
Current: $73.63
Upside: -42.96%
Exelixis
Aug 8, 2023
Initiates: Market Perform
Price Target: $18
Current: $36.98
Upside: -51.33%